



Treating Chronic Myeloid Leukemia by Phase Industry Research Report 2026

Industry	Published	Pages	Format
Pharma & Healthcare	2025-12-27	133	PDF
Single User	Multi User	Enterprise	
USD 2,950	USD 4,430	USD 5,900	

Description

The global Treating Chronic Myeloid Leukemia by Phase market was valued at US\$ million in 2025 and is projected to reach US\$ million by 2032, implying a CAGR of % over 2026–2032.

North America: the Treating Chronic Myeloid Leukemia by Phase market is projected to increase from US\$ million in 2026 to US\$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Treating Chronic Myeloid Leukemia by Phase market is projected to rise from US\$ million in 2026 to US\$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Treating Chronic Myeloid Leukemia by Phase market is expected to grow from US\$ million in 2026 to US\$ million by 2032, at a CAGR of % over 2026–2032.

Leading global service providers of Treating Chronic Myeloid Leukemia by Phase include Chia Tai Tianqing Pharmaceutical, Suzhou Thery Pharmaceutical, CSPC Ouyi Pharmaceutical, Qilu Pharmaceutical, Lunan Pharmaceutical, Hansoh Pharmaceutical, Teva, Takeda Pharmaceuticals and Sun Pharmaceuticals, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.

Report Scope

This report quantifies the global Treating Chronic Myeloid Leukemia by Phase market in terms of revenue (US\$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.

It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US\$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Treating Chronic Myeloid Leukemia by Phase.

Key Companies & Market Share Insights

This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.

Treating Chronic Myeloid Leukemia by Phase Market by Company

Chia Tai Tianqing Pharmaceutical

Suzhou Thery Pharmaceutical

CSPC Ouyi Pharmaceutical

Qilu Pharmaceutical
Lunan Pharmaceutical
Hansoh Pharmaceutical
Teva
Takeda Pharmaceuticals
Sun Pharmaceuticals
Sawai Pharmaceutical
Pfizer
Novartis
Mylan
Lupin
Hetero
Eugia Pharma
Dr. Reddy's Laboratories
Bristol Myers Squibb
Apotex

Treating Chronic Myeloid Leukemia by Phase Segment by Type

Blast Phase
Accelerated Phase
Chronic Phase

Treating Chronic Myeloid Leukemia by Phase Segment by Application

Hospitals
Clinics
Others

Treating Chronic Myeloid Leukemia by Phase Segment by Region

North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia

South America

Brazil

Argentina

Chile

Colombia

Middle East & Africa

Saudi Arabia

Israel

United Arab Emirates

Turkey

Iran

Egypt

Key Drivers & Barriers

High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Treating Chronic Myeloid Leukemia by Phase market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Treating Chronic Myeloid Leukemia by Phase and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Treating Chronic Myeloid Leukemia by Phase.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1:

Research objectives, research methods, data sources, data cross-validation;

Chapter 2:

Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 3:

Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 4:

Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 5:

Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.

Chapter 6:

Detailed analysis of Treating Chronic Myeloid Leukemia by Phase companies' competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 12:

Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 13:

The main points and conclusions of the report.

Table of Contents

1 Preface

- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
 - 1.5.1 Secondary Sources
 - 1.5.2 Primary Sources

2 Market Overview

- 2.1 Product Definition
- 2.2 Treating Chronic Myeloid Leukemia by Phase by Type
 - 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
 - 2.2.2 Blast Phase
 - 2.2.3 Accelerated Phase
 - 2.2.4 Chronic Phase
- 2.3 Treating Chronic Myeloid Leukemia by Phase by Application
 - 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
 - 2.3.2 Hospitals
 - 2.3.3 Clinics
 - 2.3.4 Others
- 2.4 Assumptions and Limitations

3 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Type

- 3.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Type (2021-2026)
- 3.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (2027-2032)

4 Treating Chronic Myeloid Leukemia by Phase Breakdown Data by Application

- 4.1 Global Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Application (2021-2026)
- 4.2 Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (2027-2032)

5 Global Growth Trends

- 5.1 Global Treating Chronic Myeloid Leukemia by Phase Market Perspective (2021-2032)
- 5.2 Global Treating Chronic Myeloid Leukemia by Phase Growth Trends by Region
 - 5.2.1 Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region: 2021 VS 2025 VS 2032
 - 5.2.2 Treating Chronic Myeloid Leukemia by Phase Historic Market Size by Region (2021-2026)
 - 5.2.3 Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (2027-2032)
- 5.3 Treating Chronic Myeloid Leukemia by Phase Market Dynamics
 - 5.3.1 Treating Chronic Myeloid Leukemia by Phase Industry Trends
 - 5.3.2 Treating Chronic Myeloid Leukemia by Phase Market Drivers
 - 5.3.3 Treating Chronic Myeloid Leukemia by Phase Market Challenges
 - 5.3.4 Treating Chronic Myeloid Leukemia by Phase Market Restraints

6 Market Competitive Landscape by Players

- 6.1 Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue
 - 6.1.1 Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue (2021-2026)

- 6.1.2 Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Players (2021-2026)
- 6.2 Global Treating Chronic Myeloid Leukemia by Phase Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Treating Chronic Myeloid Leukemia by Phase Head Office and Area Served
- 6.4 Global Treating Chronic Myeloid Leukemia by Phase Players, Product Type & Application
- 6.5 Global Treating Chronic Myeloid Leukemia by Phase Manufacturers Established Date
- 6.6 Global Treating Chronic Myeloid Leukemia by Phase Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition

7 North America

- 7.1 North America Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 7.2 North America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 7.4 North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico

8 Europe

- 8.1 Europe Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 8.2 Europe Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 8.4 Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries

9 Asia-Pacific

- 9.1 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 9.2 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia

10 South America

- 10.1 South America Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 10.2 South America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 10.4 South America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 10.5 Brazil

- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru

11 Middle East & Africa

- 11.1 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size (2021-2032)
- 11.2 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt

12 Players Profiled

- 12.1 Chia Tai Tianqing Pharmaceutical
 - 12.1.1 Chia Tai Tianqing Pharmaceutical Company Information
 - 12.1.2 Chia Tai Tianqing Pharmaceutical Business Overview
 - 12.1.3 Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
 - 12.1.4 Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
 - 12.1.5 Chia Tai Tianqing Pharmaceutical Recent Developments
- 12.2 Suzhou Thery Pharmaceutical
 - 12.2.1 Suzhou Thery Pharmaceutical Company Information
 - 12.2.2 Suzhou Thery Pharmaceutical Business Overview
 - 12.2.3 Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
 - 12.2.4 Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
 - 12.2.5 Suzhou Thery Pharmaceutical Recent Developments
- 12.3 CSPC Ouyi Pharmaceutical
 - 12.3.1 CSPC Ouyi Pharmaceutical Company Information
 - 12.3.2 CSPC Ouyi Pharmaceutical Business Overview
 - 12.3.3 CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
 - 12.3.4 CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
 - 12.3.5 CSPC Ouyi Pharmaceutical Recent Developments
- 12.4 Qilu Pharmaceutical
 - 12.4.1 Qilu Pharmaceutical Company Information
 - 12.4.2 Qilu Pharmaceutical Business Overview
 - 12.4.3 Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
 - 12.4.4 Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
 - 12.4.5 Qilu Pharmaceutical Recent Developments
- 12.5 Lunan Pharmaceutical
 - 12.5.1 Lunan Pharmaceutical Company Information
 - 12.5.2 Lunan Pharmaceutical Business Overview
 - 12.5.3 Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
 - 12.5.4 Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
 - 12.5.5 Lunan Pharmaceutical Recent Developments
- 12.6 Hansoh Pharmaceutical

12.6.1 Hansoh Pharmaceutical Company Information

12.6.2 Hansoh Pharmaceutical Business Overview

12.6.3 Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.6.4 Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.6.5 Hansoh Pharmaceutical Recent Developments

12.7 Teva

12.7.1 Teva Company Information

12.7.2 Teva Business Overview

12.7.3 Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.7.4 Teva Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.7.5 Teva Recent Developments

12.8 Takeda Pharmaceuticals

12.8.1 Takeda Pharmaceuticals Company Information

12.8.2 Takeda Pharmaceuticals Business Overview

12.8.3 Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.8.4 Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.8.5 Takeda Pharmaceuticals Recent Developments

12.9 Sun Pharmaceuticals

12.9.1 Sun Pharmaceuticals Company Information

12.9.2 Sun Pharmaceuticals Business Overview

12.9.3 Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.9.4 Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.9.5 Sun Pharmaceuticals Recent Developments

12.10 Sawai Pharmaceutical

12.10.1 Sawai Pharmaceutical Company Information

12.10.2 Sawai Pharmaceutical Business Overview

12.10.3 Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.10.4 Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.10.5 Sawai Pharmaceutical Recent Developments

12.11 Pfizer

12.11.1 Pfizer Company Information

12.11.2 Pfizer Business Overview

12.11.3 Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.11.4 Pfizer Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.11.5 Pfizer Recent Developments

12.12 Novartis

12.12.1 Novartis Company Information

12.12.2 Novartis Business Overview

12.12.3 Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.12.4 Novartis Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.12.5 Novartis Recent Developments

12.13 Mylan

12.13.1 Mylan Company Information

12.13.2 Mylan Business Overview

12.13.3 Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.13.4 Mylan Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.13.5 Mylan Recent Developments

12.14 Lupin

12.14.1 Lupin Company Information

12.14.2 Lupin Business Overview

12.14.3 Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.14.4 Lupin Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.14.5 Lupin Recent Developments

12.15 Hetero

12.15.1 Hetero Company Information

12.15.2 Hetero Business Overview

12.15.3 Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.15.4 Hetero Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.15.5 Hetero Recent Developments

12.16 Eugia Pharma

12.16.1 Eugia Pharma Company Information

12.16.2 Eugia Pharma Business Overview

12.16.3 Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.16.4 Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.16.5 Eugia Pharma Recent Developments

12.17 Dr. Reddy's Laboratories

12.17.1 Dr. Reddy's Laboratories Company Information

12.17.2 Dr. Reddy's Laboratories Business Overview

12.17.3 Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.17.4 Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.17.5 Dr. Reddy's Laboratories Recent Developments

12.18 Bristol Myers Squibb

12.18.1 Bristol Myers Squibb Company Information

12.18.2 Bristol Myers Squibb Business Overview

12.18.3 Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.18.4 Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.18.5 Bristol Myers Squibb Recent Developments

12.19 Apotex

12.19.1 Apotex Company Information

12.19.2 Apotex Business Overview

12.19.3 Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)

12.19.4 Apotex Treating Chronic Myeloid Leukemia by Phase Product Portfolio

12.19.5 Apotex Recent Developments

13 Report Conclusion

14 Disclaimer

List of Tables and Figures

List of Tables:

- Table 1: Secondary Sources
- Table 2: Primary Sources
- Table 3: Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 4: Market Value Comparison by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Table 5: Global Treating Chronic Myeloid Leukemia by Phase Market Size by Type (2021-2026) & (US\$ Million)
- Table 6: Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Type (2021-2026)
- Table 7: Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Type (2027-2032) & (US\$ Million)
- Table 8: Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Type (2027-2032)
- Table 9: Global Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2021-2026) & (US\$ Million)
- Table 10: Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Application (2021-2026)
- Table 11: Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Application (2027-2032) & (US\$ Million)
- Table 12: Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Application (2027-2032)
- Table 13: Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region (US\$ Million): 2021 VS 2025 VS 2032
- Table 14: Global Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2021-2026) & (US\$ Million)
- Table 15: Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2021-2026)
- Table 16: Global Treating Chronic Myeloid Leukemia by Phase Forecasted Market Size by Region (2027-2032) & (US\$ Million)
- Table 17: Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region (2027-2032)
- Table 18: Treating Chronic Myeloid Leukemia by Phase Industry Trends
- Table 19: Treating Chronic Myeloid Leukemia by Phase Industry Drivers
- Table 20: Treating Chronic Myeloid Leukemia by Phase Industry Opportunities and Challenges
- Table 21: Treating Chronic Myeloid Leukemia by Phase Market Restraints
- Table 22: Global Top Treating Chronic Myeloid Leukemia by Phase Players by Revenue (US\$ Million) & (2021-2026)
- Table 23: Global Treating Chronic Myeloid Leukemia by Phase Revenue Market Share by Players (2021-2026)
- Table 24: Global Treating Chronic Myeloid Leukemia by Phase Industry Players Ranking, 2024 VS 2025 VS 2026
- Table 25: Global Key Players of Treating Chronic Myeloid Leukemia by Phase, Headquarters and Area Served
- Table 26: Global Treating Chronic Myeloid Leukemia by Phase Players, Product Type & Application
- Table 27: Global Players Market Concentration Ratio (CR5 and HHI)
- Table 28: Global Treating Chronic Myeloid Leukemia by Phase by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025)
- Table 29: Players Mergers & Acquisitions, Expansion Plans
- Table 30: North America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 31: North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026) & (US\$ Million)
- Table 32: North America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032) & (US\$ Million)
- Table 33: Europe Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 34: Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026) & (US\$ Million)
- Table 35: Europe Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032) & (US\$ Million)
- Table 36: Asia Pacific Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 37: Asia Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Region (2021-2026) & (US\$ Million)
- Table 38: Asia Pacific Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032) & (US\$ Million)
- Table 39: South America Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 40: South America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026) & (US\$ Million)
- Table 41: South America Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032) & (US\$ Million)
- Table 42: Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Growth Rate by Country: 2021 VS 2025 VS 2032 (US\$ Million)
- Table 43: Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2021-2026) & (US\$ Million)
- Table 44: Middle East & Africa Treating Chronic Myeloid Leukemia by Phase Market Size by Country (2027-2032) & (US\$ Million)
- Table 45: Chia Tai Tianqing Pharmaceutical Company Information
- Table 46: Chia Tai Tianqing Pharmaceutical Business Overview

- Table 47: Chia Tai Tianqing Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 48: Chia Tai Tianqing Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 49: Chia Tai Tianqing Pharmaceutical Recent Developments
- Table 50: Suzhou Thery Pharmaceutical Company Information
- Table 51: Suzhou Thery Pharmaceutical Business Overview
- Table 52: Suzhou Thery Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 53: Suzhou Thery Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 54: Suzhou Thery Pharmaceutical Recent Developments
- Table 55: CSPC Ouyi Pharmaceutical Company Information
- Table 56: CSPC Ouyi Pharmaceutical Business Overview
- Table 57: CSPC Ouyi Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 58: CSPC Ouyi Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 59: CSPC Ouyi Pharmaceutical Recent Developments
- Table 60: Qilu Pharmaceutical Company Information
- Table 61: Qilu Pharmaceutical Business Overview
- Table 62: Qilu Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 63: Qilu Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 64: Qilu Pharmaceutical Recent Developments
- Table 65: Lunan Pharmaceutical Company Information
- Table 66: Lunan Pharmaceutical Business Overview
- Table 67: Lunan Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 68: Lunan Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 69: Lunan Pharmaceutical Recent Developments
- Table 70: Hansoh Pharmaceutical Company Information
- Table 71: Hansoh Pharmaceutical Business Overview
- Table 72: Hansoh Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 73: Hansoh Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 74: Hansoh Pharmaceutical Recent Developments
- Table 75: Teva Company Information
- Table 76: Teva Business Overview
- Table 77: Teva Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 78: Teva Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 79: Teva Recent Developments
- Table 80: Takeda Pharmaceuticals Company Information
- Table 81: Takeda Pharmaceuticals Business Overview
- Table 82: Takeda Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 83: Takeda Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 84: Takeda Pharmaceuticals Recent Developments
- Table 85: Sun Pharmaceuticals Company Information
- Table 86: Sun Pharmaceuticals Business Overview
- Table 87: Sun Pharmaceuticals Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 88: Sun Pharmaceuticals Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 89: Sun Pharmaceuticals Recent Developments
- Table 90: Sawai Pharmaceutical Company Information
- Table 91: Sawai Pharmaceutical Business Overview
- Table 92: Sawai Pharmaceutical Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 93: Sawai Pharmaceutical Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 94: Sawai Pharmaceutical Recent Developments
- Table 95: Pfizer Company Information
- Table 96: Pfizer Business Overview
- Table 97: Pfizer Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 98: Pfizer Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 99: Pfizer Recent Developments
- Table 100: Novartis Company Information
- Table 101: Novartis Business Overview
- Table 102: Novartis Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 103: Novartis Treating Chronic Myeloid Leukemia by Phase Product Portfolio

- Table 104: Novartis Recent Developments
- Table 105: Mylan Company Information
- Table 106: Mylan Business Overview
- Table 107: Mylan Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 108: Mylan Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 109: Mylan Recent Developments
- Table 110: Lupin Company Information
- Table 111: Lupin Business Overview
- Table 112: Lupin Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 113: Lupin Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 114: Lupin Recent Developments
- Table 115: Hetero Company Information
- Table 116: Hetero Business Overview
- Table 117: Hetero Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 118: Hetero Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 119: Hetero Recent Developments
- Table 120: Eugia Pharma Company Information
- Table 121: Eugia Pharma Business Overview
- Table 122: Eugia Pharma Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 123: Eugia Pharma Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 124: Eugia Pharma Recent Developments
- Table 125: Dr. Reddy's Laboratories Company Information
- Table 126: Dr. Reddy's Laboratories Business Overview
- Table 127: Dr. Reddy's Laboratories Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 128: Dr. Reddy's Laboratories Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 129: Dr. Reddy's Laboratories Recent Developments
- Table 130: Bristol Myers Squibb Company Information
- Table 131: Bristol Myers Squibb Business Overview
- Table 132: Bristol Myers Squibb Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 133: Bristol Myers Squibb Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 134: Bristol Myers Squibb Recent Developments
- Table 135: Apotex Company Information
- Table 136: Apotex Business Overview
- Table 137: Apotex Revenue in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026) & (US\$ Million)
- Table 138: Apotex Treating Chronic Myeloid Leukemia by Phase Product Portfolio
- Table 139: Apotex Recent Developments
- Table 140: Authors List of This Report

List of Figures:

- Figure 1: Research Methodology
- Figure 2: Research Process
- Figure 3: Key Executives Interviewed
- Figure 4: Treating Chronic Myeloid Leukemia by Phase Product Image
- Figure 5: Global Treating Chronic Myeloid Leukemia by Phase Market Size Comparison by Type (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 6: Global Treating Chronic Myeloid Leukemia by Phase Market Share by Type: 2025 VS 2032
- Figure 7: Blast Phase Product
- Figure 8: Accelerated Phase Product
- Figure 9: Chronic Phase Product
- Figure 10: Global Treating Chronic Myeloid Leukemia by Phase Market Size by Application (2021 VS 2025 VS 2032) & (US\$ Million)
- Figure 11: Global Treating Chronic Myeloid Leukemia by Phase Market Share by Application: 2025 VS 2032
- Figure 12: Hospitals Product
- Figure 13: Clinics Product
- Figure 14: Others Product
- Figure 15: Global Treating Chronic Myeloid Leukemia by Phase Market Size (US\$ Million), Year-over-Year: 2021-2032
- Figure 16: Global Treating Chronic Myeloid Leukemia by Phase Market Size, (US\$ Million), 2021 VS 2025 VS 2032
- Figure 17: Global Treating Chronic Myeloid Leukemia by Phase Market Share by Region: 2025 VS 2032
- Figure 18: Global Treating Chronic Myeloid Leukemia by Phase Market Share by Players in 2025
- Figure 19: Global Treating Chronic Myeloid Leukemia by Phase Manufacturers Established Date
- Figure 20: Global Top 5 and 10 Treating Chronic Myeloid Leukemia by Phase Players Market Share by Revenue in 2025

- Figure 21: Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025
- Figure 22: North America Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 23: North America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021-2032)
- Figure 24: United States Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 25: Canada Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 26: Mexico Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021-2032)
- Figure 27: Europe Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 28: Europe Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021-2032)
- Figure 29: Germany Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 30: France Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 31: U.K. Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 32: Italy Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 33: Spain Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 34: Russia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 35: Netherlands Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 36: Nordic Countries Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 37: Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 38: Asia-Pacific Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021-2032)
- Figure 39: China Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 40: Japan Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 41: South Korea Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 42: India Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 43: India Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021-2032)
- Figure 44: Australia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 45: China Taiwan Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 46: Southeast Asia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 47: South America Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 48: South America Treating Chronic Myeloid Leukemia by Phase Market Share by Country (2021-2032)
- Figure 49: Brazil Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 50: Argentina Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 51: Chile Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 52: Colombia Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 53: Peru Treating Chronic Myeloid Leukemia by Phase Market Size YoY Growth (2021-2032) & (US\$ Million)
- Figure 54: Chia Tai Tianqing Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 55: Suzhou Thery Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 56: CSPC Ouyi Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 57: Qilu Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 58: Lunan Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 59: Hansoh Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 60: Teva Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 61: Takeda Pharmaceuticals Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 62: Sun Pharmaceuticals Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 63: Sawai Pharmaceutical Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 64: Pfizer Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 65: Novartis Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 66: Mylan Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 67: Lupin Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 68: Hetero Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 69: Eugia Pharma Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 70: Dr. Reddy's Laboratories Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 71: Bristol Myers Squibb Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)
- Figure 72: Apotex Revenue Growth Rate in Treating Chronic Myeloid Leukemia by Phase Business (2021-2026)